Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

Eli Lilly and Johnson & Johnson are compared as investment opportunities in the healthcare sector. Lilly is driven by its dominant GLP-1 franchise (Mounjaro, Zepbound) generating $27.6B in H1 2026 sales, with new oral therapy Foundayo and pipeline candidate Retatrutide offering future growth. J&J offers diversification across pharmaceuticals and medical devices with 28 products generating over $1B annually, steady 6.2% organic growth in Innovative Medicines, and 64 consecutive years of dividend increases. While J&J shows better valuation and recent stock performance (+33% YTD), Lilly is selected as the superior long-term pick due to substantially stronger earnings-growth prospects, despite facing pricing pressures and GLP-1 market competition.